Gilead Sciences, Inc.’s Sovaldi® Demonstrates Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease
Published: Apr 11, 2014
LONDON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. These data are being presented this week at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) in London.
Help employers find you! Check out all the jobs and post your resume.